Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Treasury Shares (2022 - 2024)

Historic Treasury Shares for Ocular Therapeutix (OCUL) over the last 5 years, with Q4 2025 value amounting to $4.4 million.

  • Ocular Therapeutix's Treasury Shares rose 2861.0% to $4.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 million, marking a year-over-year increase of 2861.0%. This contributed to the annual value of $4.4 million for FY2025, which is 2861.0% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Treasury Shares is $4.4 million, which was up 2861.0% from $3.4 million recorded in Q4 2024.
  • Ocular Therapeutix's Treasury Shares' 5-year high stood at $4.4 million during Q4 2025, with a 5-year trough of $1.1 million in Q4 2022.
  • In the last 4 years, Ocular Therapeutix's Treasury Shares had a median value of $2.5 million in 2023 and averaged $2.6 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Treasury Shares soared by 10829.09% in 2024, and later soared by 2861.0% in 2025.
  • Ocular Therapeutix's Treasury Shares (Quarter) stood at $1.1 million in 2022, then surged by 48.93% to $1.6 million in 2023, then soared by 108.29% to $3.4 million in 2024, then increased by 28.61% to $4.4 million in 2025.
  • Its Treasury Shares was $4.4 million in Q4 2025, compared to $3.4 million in Q4 2024 and $1.6 million in Q4 2023.